Allergy Immunotherapy Success Rate: SCIT vs SLIT Evidence by Allergen

Allergy immunotherapy achieves clinically meaningful symptom improvement in roughly 50–80% of treated patients, with the exact rate depending on allergen type, treatment duration, and the definition of 'success.' The Calderon Cochrane review (2007, 51 RCTs) found a pooled standardized mean difference of −0.73 for symptom scores with SCIT versus placebo — roughly a one-third reduction. For house dust mite specifically, Lee et al. (2018, n=304) reported 76.6% cumulative clinical remission at a median 4.9 years. Grass pollen and dust mite show the strongest evidence; cockroach and dog show weak evidence. Completing at least 3 years of treatment is the single strongest predictor of lasting benefit.

For long-term disease modification, immunotherapy is substantially more effective than antihistamines, though in head-to-head direct comparisons for short-term symptom control, intranasal corticosteroids perform similarly. Matricardi et al. (2011) calculated that SCIT produced a 34.7% relative reduction in nasal symptom scores, compared to 31.7% for mometasone and only 12.0% for desloratadine. The unique advantage of immunotherapy is not just its comparable symptom control, but the fact that benefits persist for years after treatment ends — something antihistamines and steroids cannot provide. Immunotherapy also reduces the risk of developing asthma in children with allergic rhinitis, an effect that antihistamines do not demonstrate.

Most patients notice meaningful symptom improvement within 3 to 6 months of starting immunotherapy — often around the time they reach or approach their maintenance dose. The AAAAI/ACAAI Practice Parameter states that clinical improvement is usually observed within one year of reaching the maintenance dose (Cox et al., JACI 2011). Some patients experience earlier benefit during the buildup phase, while others require closer to 12 months. If no benefit is evident after one full year of maintenance, your allergist will reassess allergen selection, dosing, and whether to continue treatment. For lasting benefit that persists after stopping, at least 3 years of treatment is required per EAACI 2018 guidelines.

Yes, allergen type is one of the most important predictors of immunotherapy success. Grass pollen SCIT has the largest and most consistent randomized trial base, with Di Bona et al. (2012) reporting a symptom SMD of −0.92. Dust mite SCIT shows strong evidence with a symptom SMD of −0.95 in the Calderon Cochrane review (2010). Cat allergen demonstrates moderate evidence with roughly 60–72% symptom reduction in controlled chamber studies. At the other end, dog dander has weaker evidence due to extract standardization problems, and cockroach SCIT failed its primary endpoint in the CRITICAL trial (Zoratti et al., JACI 2024). Your allergist uses this allergen-specific evidence to counsel whether immunotherapy is likely to work for your specific triggers before recommending it.

Benefits from a complete 3–5-year immunotherapy course typically persist for several years after stopping — and in some cases much longer. Durham et al. (N Engl J Med, 1999) demonstrated that 3–4 years of grass SCIT produced sustained symptom control for at least 3 years post-treatment, with no meaningful difference between patients who continued maintenance and those who stopped. The longest follow-up data come from Eng et al. (Allergy, 2006), who found significant clinical benefit 12 years after childhood grass SCIT. For HDM-driven disease, Marogna et al. (2010) reported roughly 7–8 years of benefit after a 3–4-year SLIT course. The EAACI recommends a minimum of 3 years for post-treatment durability, and the Lee 2018 data show OR 7.37 for remission when treatment lasts at least 3 years.

For the most-studied allergens, SCIT and SLIT-tablets achieve broadly comparable efficacy. Nelson's 2015 network meta-analysis — the most rigorous direct comparison for grass pollen — found no statistically significant difference between SCIT and SLIT-tablets (symptom SMD difference of 0.01). Some indirect analyses favor SCIT slightly (Di Bona 2012 found SCIT SMD −0.92 vs SLIT tablet SMD −0.40 for grass), while others find equivalence. Head-to-head randomized trials are small (maximum 71 patients) and have not shown statistically significant differences. The decisive distinction is safety: SCIT carries an estimated 1 fatality per 2.5 million injections, while no SLIT fatality has ever been documented. For polysensitized patients needing custom multi-allergen treatment, SCIT holds a practical advantage because FDA-approved tablets each treat only one allergen.

Real-world completion rates are substantially lower than those observed in clinical trials. The largest adherence study — Kiel et al. (JACI 2013, n=6,486 Dutch patients) — found that only 23% of SCIT users and 7% of SLIT users completed the minimum 3-year course, with median treatment durations of 1.7 years for SCIT and 0.6 years for SLIT. US data are similarly sobering: Hankin et al. (JACI 2008) reported that 84% of pediatric Medicaid patients failed to complete 3 years, and 53% stopped within the first year. Even in a US military cohort where there were no out-of-pocket costs, only 34% reached 3 years of maintenance (Mendoza et al., 2023). Adherence is the dominant practical limitation on immunotherapy effectiveness in real-world settings.

Evidence from multiple long-term studies suggests immunotherapy significantly reduces the risk of developing asthma in children with allergic rhinitis, though a definitive randomized controlled trial with asthma diagnosis as the primary endpoint has not been completed for SCIT. The PAT study (Möller et al., JACI 2002; n=205 children with grass/birch rhinitis) found significantly fewer asthma cases in the SCIT group, and the 10-year follow-up (Jacobsen et al., Allergy 2007) confirmed asthma in 25% of treated children versus 45% of controls — an odds ratio of 2.5 in favor of SCIT 7 years after stopping treatment. The NNT is approximately 5–6 children treated to prevent one new asthma case. This asthma-prevention evidence is stronger for SCIT than for SLIT, where the GAP trial (Valovirta et al., 2018) failed its primary asthma-diagnosis endpoint.